Cequent Pharmaceuticals

Cequent is a biopharmaceutical company pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases.
  • Industry: Therapeutics
  • Founder: Johannes Fruehauf
  • Website: http://www.cequentpharma.com/
  • Location: Cambridge, Massachusetts
  • Size: 1-10 employees
  • Overview: An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.

Search 1.5 billion
Email & Phone#

Browse to anyone's Linkedin profile, and Contactout will find that person's email address and phone number

Start your free trial
(300+ Reviews)

People also viewed these companies

  • Nonprofit Organization Management
  • Accounting
  • Financial Services
  • Marketing & Advertising
  • Real Estate
  • Food Production
  • Publishing
  • Health, Wellness and Fitness